NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Artax Biopharma

Artax Biopharma

Private
Cambridge, MassachusettsHealthcare & Life Scienceshttps://artaxbiopharma.com/

Last Round

Early Stage

VC

May 5, 2026

Est. Valuation

$51.35M

Total Funding Raised

$44M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Artax Biopharma is a biotechnology company that develops small molecule drugs designed to treat autoimmune and inflammatory diseases by targeting T cell-mediated immune responses.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

immunomodulatorsmall-molecule drugT cell-mediated diseaseautoimmune therapyNck modulatorclinical-stage biotechdrug discoveryT cell receptorTCRbiopharmainflammatory disease treatmentoral drugdrug licensingpipeline drug

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Artax Biopharma Comparables

Compare Artax Biopharma with similar companies based on industry and business-model similarity.

Artax Biopharma comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Revolo Biotherapeutics
71%
Johnson & Johnson
71%
Bristol Myers Squibb
70%

Artax Biopharma Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Early Stage VCMay 5, 2026
Convertible DebtAug 6, 2024
Series CMay 11, 2022
Series B ExtensionJun 4, 2020
Series BSep 22, 2015

Key People

Founding team and executive leadership

Rob Armstrong

President And Chief Executive Officer

Executive Team

Andy Gagete Mateos

COO

Executive Team

Artax Biopharma Investors

Notable investors and investment history

Artax Biopharma investors
InvestorRounds
Columbus VenturesConvertible Debt
A. M. Pappas & AssociatesSeries B
Advent Life SciencesConvertible Debt, Series C, Series B
Columbus Venture PartnersConvertible Debt, Series C, Series B Extension
Sound BioventuresConvertible Debt, Series C

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 5, 2026

    $19M raised in early stage VC round.

  • Mar 7, 2025

    Presented preclinical data at the 2025 American Academy of Dermatology Annual Meeting.

Artax Biopharma Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Artax Biopharma Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Artax Biopharma's valuation, stock price, and market status.

Firmographic Details

HeadquartersCambridge, Massachusetts
Employee Range13
Year Founded2013
Last FundingMay 5, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.